Brief: Jhbp Cy Says NMPA Grants New Approval For Phase I/Ii Clinical Trials Of Gb261 (Cd20/Cd3 Bsab)
24/05/2022 13:34
May 24 (Reuters) - Genor Biopharma Holdings Ltd 6998.HK :
* NMPA GRANTS NEW APPROVAL FOR PHASE I/II CLINICAL TRIALS OF
GB261
(CD20/CD3 BSAB)
Source text for Eikon: ID:nHKS8hbqWJ
Further company coverage: 6998.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Edding Genor group
See all newsBrief: JHBP CY Says Chairman And CEO Ni Xin To Buy Shares Up To USD 1 Million From Aug 31, 2026
Brief: Edding Genor Group Expects Revenue Of RMB850 MLN-RMB900 MLN For HY
Brief: Jhbp Cy Disposal Of Equity Interest In Candid Therapeutics
Edding Genor climbs on approval of clinical trial of cancer drug in China
Brief: JHBP CY's Phase Ib/Ii Clinical Trial Of Gb268 Obtains IND Approval By NMPA